Apr 26, 2017

Integra LifeSciences Reports First Quarter 2017 Financial Results

Revenue Increased 9.2% to $258.6 million; Organic Revenue Increased 6.4%

 Reported EPS of $0.08; Adjusted EPS of $0.39

PLAINSBORO, N.J., April 26, 2017 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, today reported its financial results for the first quarter ending March 31, 2017.

Highlights:

Total revenues for the first quarter were $258.6 million, reflecting an increase of $21.9 million, or 9.2%, over the first quarter of 2016. Both global segments contributed to the growth, with revenue in Orthopedics and Tissue Technologies and Specialty Surgical Solutions increasing by 19.6% and 3.4%, respectively, compared to the prior year.

Excluding the revenue contribution from acquisitions and the effect of currency exchange rates and discontinued products, revenues increased 6.4% over the first quarter of 2016.

"We are off to a solid start in 2017, which gives us increased confidence in delivering on our full-year 2017 financial guidance," said Peter Arduini, Integra's president and chief executive officer. "We completed the acquisition of Derma Sciences, launched several new products that will drive growth in the second half of the year, and remain on track to complete the planned acquisition of Codman Neurosurgery in the fourth quarter of 2017."

The company reported GAAP net income of $6.4 million, or $0.08 per diluted share, for the first quarter of 2017, compared to a GAAP net income of $13.4 million, or $0.18 per diluted share, for the first quarter of 2016. The year-over-year declines largely resulted from acquisition-related expenses associated with the Derma Sciences and Codman Neurosurgery transactions.

The adjusted measures discussed below are computed with the adjustments to GAAP reporting set forth in the attached reconciliation.

Adjusted net income for the first quarter of 2017 was $30.9 million, an increase of 9.3% over the prior year, and compares to adjusted net income of $28.3 million in the first quarter of 2016. Adjusted earnings per share for the first quarter of 2017 was $0.39, compared to $0.38, in the first quarter of 2016.

Adjusted EBITDA for the first quarter of 2017 was $55.2 million, or 21.3% of revenue, compared to $52.1 million, or 22.0% of revenue, in the first quarter of 2016. The slight decrease in adjusted EBITDA margin primarily resulted from the dilution caused by the Derma Sciences acquisition.

Operating cash flow for the first quarter was $28.9 million, an increase of 15.4% from the prior-year period.  Trailing twelve-month adjusted free cash flow conversion ended March 31, 2017 was 85.1%, versus 65.4% in the prior year.

Outlook for 2017

Based on first quarter results and the outlook for the remainder of the year, the company is maintaining its full-year 2017 revenue guidance range of $1.12 billion to $1.14 billion, and full-year 2017 organic revenue growth range of 7.0% to 8.5%. The company also is maintaining its full-year GAAP and adjusted earnings per share guidance ranges of $0.49 to $0.55 and $1.88 to $1.94, respectively.

"Based on our first quarter results and the sequential improvements that we expect over the course of the year, we remain confident that we will achieve our full-year projections," said Glenn Coleman, Integra's chief financial officer. "We also successfully executed and secured an extension of our term loan facility with favorable terms, which we will use to pay for the planned acquisition of Codman Neurosurgery later this year."

In the future, the company may record, or expects to record, certain additional revenues, gains, expenses, or charges as described in the Discussion of Adjusted Financial Measures below which will be excluded from the calculation of adjusted EBITDA, adjusted earnings per share for historical periods and in adjusted earnings per share guidance.

Conference Call and Presentation Available Online

Integra has scheduled a conference call for 8:30 AM ET today, Wednesday, April 26, 2017, to discuss financial results for the first quarter and forward-looking financial guidance.  The conference call will be hosted by Integra's senior management team and will be open to all listeners.  Additional forward-looking information may be discussed in a question and answer session following the call.

Integra's management team will reference a presentation during the conference call.  That presentation can be found on investor.integralife.com.

Access to the live call is available by dialing (719) 457-2618 and using the passcode 3686388. The call can also be accessed via a webcast link provided on investor.integralife.com.  Access to the replay will be available through May 1, 2017, by dialing (719) 457-0820 and using the passcode 3686388. The webcast will also be archived on the website.

Integra LifeSciences is dedicated to limiting uncertainty for clinicians, so they can concentrate on providing the best patient care. Integra offers innovative solutions, including leading plastic and regenerative technologies, in specialty surgical solutions and orthopedics and tissue technologies. For more information, please visit www.integralife.com

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks, uncertainties and reflect the Company's judgment as of the date of this release.  Forward-looking statements include, but are not limited to, statements concerning future financial performance, including projections for revenues, GAAP and adjusted net income, GAAP and adjusted (loss)/earnings per diluted share, non-GAAP adjustments such as global enterprise resource planning ("ERP") system implementation charges, acquisition-related charges, goodwill impairment charges, non-cash amortization of imputed interest for convertible debt, intangible asset amortization, and income tax expense (benefit) related to non-GAAP adjustments. Such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from predicted or expected results. Such risks and uncertainties include, but are not limited to the following: the Company's ability to execute its operating plan effectively; the Company's ability to manufacture and ship sufficient quantities of its products to meet its customers' demand; the ability of third-party suppliers to supply us with raw materials and finished products; global macroeconomic and political conditions; the Company's ability to manage its direct sales channels effectively; the Company's ability to maintain relationships with customers of acquired entities; physicians' willingness to adopt and third-party payors' willingness to provide or maintain reimbursement for the Company's recently launched, planned and existing products; initiatives launched by the Company's competitors; downward pricing pressures for customers; the Company's ability to secure regulatory approval for products in development; the Company's ability to remediate quality systems violations; fluctuations in hospitals spending for capital equipment; the Company's ability to comply with and obtain approvals for products of human origin and comply with recently enacted regulations regarding products containing materials derived from animal sources; difficulties in controlling expenses, including costs to procure and manufacture our products; the impact of changes in management or staff levels; the Company's ability to integrate acquired businesses; the impact of goodwill and intangible asset impairment charges if future operating results of acquired businesses are significantly less than the results anticipated at the time of the acquisitions, the Company's ability to leverage its existing selling organizations and administrative infrastructure; the Company's ability to increase product sales and gross margins, and control non-product costs; the Company's ability to achieve anticipated growth rates, margins and scale and execute its strategy generally; the amount and timing of acquisition, and integration-related costs; the geographic distribution of where the Company generates its taxable income; the effect of legislation effecting healthcare reform in the United States and internationally; fluctuations in foreign currency exchange rates; the amount of our convertible notes and bank borrowings outstanding and other factors influencing liquidity; and the economic, competitive, governmental, technological, and other risk factors and uncertainties identified under the heading "Risk Factors" included in Item 1A of Integra's Annual Report on Form 10-K for the year ended December 31, 2016 and information contained in subsequent filings with the Securities and Exchange Commission.  In addition, with respect to the Codman Neurosurgery acquisition, forward-looking statements in this document may include without limitation any statements regarding the planned completion of the proposed acquisition, the costs and benefits of the proposed acquisition, including future financial and operating results, Integra's or the Codman Neurosurgery business's plans, objectives, expectations and intentions and the expected timing of completion of the proposed acquisition.   It is important to note that Integra's goals and expectations are not predictions of actual performance.  Actual results may differ materially from Integra's current expectations depending upon a number of factors affecting the Codman Neurosurgery business and Integra's business and risks and uncertainties associated with acquisition transactions.  These factors include, among other things, the following: successful closing of the proposed acquisition; the risk that competing offers will be made for the Codman Neurosurgery business before the binding offer is accepted; the risk that the binding offer may not be accepted on a timely basis or at all; the ability to obtain required regulatory approvals for the proposed acquisition (including the approval of antitrust authorities necessary to complete the proposed acquisition), the timing of obtaining such approvals and the risk that such approvals may result in the imposition of conditions, including with respect to divestitures, that could materially adversely affect Integra, the Codman Neurosurgery business and the expected benefits of the proposed acquisition; the risk that a condition to closing of the proposed acquisition may not be satisfied on a timely basis or at all; the failure of the proposed acquisition to close for any other reason and the risk liability to Integra in connection therewith; access to available financing (including financing for the acquisition) on a timely basis and on reasonable terms; the effects of disruption caused by the proposed acquisition making it more difficult for Integra to execute its operating plan effectively or to maintain relationships with employees, vendors and other business partners; stockholder litigation in connection with the proposed acquisition; and  Integra's ability to successfully integrate the Codman Neurosurgery business and other acquired businesses.

These forward-looking statements are made only as of the date hereof, and the Company undertakes no obligation to update or revise the forward-looking statements, whether as a result of new information, future events, or otherwise.

Discussion of Adjusted Financial Measures

In addition to our GAAP results, we provide organic revenues, adjusted earnings before interest, taxes, depreciation and amortization ("EBITDA"), adjusted net income, adjusted earnings per diluted share, adjusted diluted weighted average shares outstanding, free cash flow and adjusted free cash flow conversion.  Organic revenues consist of total revenues excluding the effects of currency exchange rates, acquired revenues and product discontinuances.  Adjusted EBITDA consists of GAAP net income from continuing operations, excluding: (i) depreciation and amortization; (ii) other income (expense); (iii) interest income and expense; (iv) income taxes; and (v) those operating expenses also excluded from adjusted net income.  The measure of adjusted net income consists of GAAP net income from continuing operations, excluding: (i) global enterprise resource planning ("ERP") implementation charges; (ii) structural optimization charges; (iii) certain employee severance charges; (iv) acquisition-related charges; (v) convertible debt non-cash interest; (vi) intangible asset amortization expense; (vii) discontinued product lines charges; and (viii) income tax impact from adjustments and other items.  The measure of adjusted diluted weighted average shares outstanding is calculated by adding the economic benefit of the convertible note hedge transactions relating to Integra's 2016 convertible notes.  The adjusted earnings per diluted share measure is calculated by dividing adjusted net income attributable to diluted shares by adjusted diluted weighted average shares outstanding.  The measure of free cash flow consists of GAAP net cash provided by continuing operating activities from continuing operations less purchases of property and equipment.  The adjusted free cash flow conversion measure is calculated by dividing free cash flow by adjusted net income. 

Reconciliations of GAAP revenues to adjusted revenues and GAAP Adjusted Net Income from continuing operations to adjusted EBITDA, and adjusted net income, and GAAP earnings per diluted share to adjusted earnings per diluted share all for the three months ended March 31, 2017 and 2016, and the free cash flow and free cash flow conversion for the three months ended March 31, 2017 and 2016 and the twelve months ended March 31, 2017 and 2016, appear in the financial tables in this release.

The Company believes that the presentation of organic revenues and the various adjusted EBITDA, adjusted net income, adjusted earnings per diluted share, adjusted diluted weighted average shares outstanding, free cash flow and free cash flow conversion measures provide important supplemental information to management and investors regarding financial and business trends relating to the Company's financial condition and results of operations.  For further information regarding why Integra believes that these non-GAAP financial measures provide useful information to investors, the specific manner in which management uses these measures, and some of the limitations associated with the use of these measures, please refer to the Company's Current Report on Form 8-K regarding this earnings press release filed today with the Securities and Exchange Commission.  This Current Report on Form 8-K is available on the SEC's website at www.sec.gov or on our website at www.integralife.com

INTEGRA LIFESCIENCES HOLDINGS CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(UNAUDITED)
 
(In thousands, except per share amounts)
 
 Three Months Ended March 31,
 2017 2016
Total revenues, net$258,636  $236,770 
    
Costs and expenses:   
Cost of goods sold86,585  84,773 
Research and development15,494  14,451 
Selling, general and administrative142,497  111,975 
Intangible asset amortization4,101  3,471 
Total costs and expenses248,677  214,670 
    
Operating income9,959  22,100 
    
Interest income7  6 
Interest expense(5,131) (6,373)
Other income (expense), net(90) (738)
Income from continuing operations before taxes4,745  14,995 
Income tax expense(1,649) 1,576 
Net income$6,394  $13,419 
    
Net income per share:   
Diluted net income per share$0.08  $0.18 
    
Weighted average common shares outstanding for diluted net income per share    78,394  76,466 

Segment revenues and growth in total revenues excluding the effects of currency exchange rates, acquisitions, and discontinued products are as follows:

(In thousands) 
  
    Three Months Ended March 31,  
  2017  2016 Change
Specialty Surgical Solutions$156,290 $151,175 3.4%
Orthopedics and Tissue Technologies 102,346  85,595 19.6%
Total revenue$258,636 $236,770 9.2%
    
Impact of changes in currency exchange rates$1,365 $  
Less contribution of revenues from acquisitions* (10,404)   
Less contribution of revenues from discontinued products   (433) (2,541) 
Total organic revenues$249,164 $234,229 6.4%
    
* Acquisitions include Derma Sciences
 

Items included in GAAP net income from continuing operations and location where each item is recorded are as follows:

(In thousands)
 
Three Months Ended March 31, 2017
 
Item  Total Amount    COGS(a)    SG&A(b)    R&D(c)    Amort.(d)    OI&E(e)  Tax(f)
Global ERP implementation charges$2,427 $$2,427$$$$ 
Structural optimization charges 1,586  898 688     
Acquisition-related charges* 20,317  643 19,674     
Certain employee severance charges 125   125     
Discontinued product lines charges 1,025  1,025      
Intangible asset amortization expense 10,966  6,865   4,101   
Estimated income tax impact from above adjustments and other items (11,951)       (11,951) 
Total adjustments$24,495 $9,431$22,914$$4,101$$(11,951) 
        
Depreciation expense 8,751        
                 
a)  COGS - Cost of goods sold 
b)  SG&A - Selling, general and administrative 
c)  R&D- Research and development 
d)  Amort. - Intangible asset amortization 
e)  OI&E - Interest (income) expense, net and other (income) expense, net 
f)  Tax - Income tax expense 
                 
* Acquisition related charges are primarily associated with the Derma Sciences and Codman Neurosurgery acquisitions and include banking, legal, consulting and other expenses


Three months ended March 31, 2016
 
(In thousands)
 
Item  Total Amount    COGS (a)    SG&A (b)    Amort. (c)    OI&E (d)   Tax (e) 
Global ERP implementation charges$3,324 $$3,324$$$ 
Structural optimization charges 1,709  985 724    
Acquisition-related charges 6,041  3,652 2,389    
Certain employee severance charges 650  211 439    
Intangible asset amortization expense 10,536  7,065  3,471   
Convertible debt noncash interest 2,064     2,064  
Estimated income tax impact from above adjustments and other items (9,480)      (9,480) 
Total adjustments$14,844 $11,913$6,876$3,471$2,064$(9,480) 
       
Depreciation expense 7,717       
 
a)  COGS - Cost of goods sold
b)  SG&A - Selling, general and administrative
c)  Amort. - Intangible asset amortization
d)  OI&E - Interest (income) expense, net and other (income) expense, net
e)  Tax - Income tax expense


RECONCILIATION OF NON-GAAP ADJUSTMENTS - GAAP NET INCOME FROM CONTINUING OPERATIONS TO ADJUSTED EBITDA
(UNAUDITED)
(In thousands, except per share amounts)
 
 Three Months Ended March 31,
  2017   2016 
GAAP net income from continuing operations$6,394  $13,419 
Non-GAAP adjustments:   
Depreciation and intangible asset amortization expense19,717  18,253 
Other (income) expense, net90  738 
Interest expense, net5,124  6,367 
Income tax expense(1,649) 1,576 
Global ERP implementation charges2,427  3,324 
Structural optimization charges1,586  1,709 
Acquisition-related charges20,317  6,041 
Certain employee severance charges125  650 
Discontinued product lines charges1,025   
    
Total of non-GAAP adjustments48,762  38,658 
Adjusted EBITDA$55,156  $52,077 
    


RECONCILIATION OF NON-GAAP ADJUSTMENTS - GAAP NET INCOME FROM CONTINUING OPERATIONS TO 
MEASURES OF ADJUSTED NET INCOME AND ADJUSTED EARNINGS PER SHARE
(UNAUDITED)
 
(In thousands, except per share amounts)
 
 Three Months Ended March 31,
 2017 2016
        
GAAP net income from continuing operations$6,394  $13,419 
Non-GAAP adjustments:   
Global ERP implementation charges2,427  3,324 
Structural optimization charges1,586  1,709 
Acquisition-related charges20,317  6,041 
Certain employee severance charges125  650 
Discontinued product lines charges1,025   
Intangible asset amortization expense10,966  10,536 
Convertible debt noncash interest  2,064 
Estimated income tax impact from adjustments and other items(11,951) (9,480)
    
Total of non-GAAP adjustments24,495  14,844 
Adjusted net income$30,889  $28,263 
    
Adjusted diluted net income per share$0.39  $0.38 
      
Weighted average common shares outstanding for diluted net income per share78,394  76,466 
Weighted average common shares outstanding adjustment for economic benefit of convertible bond hedge transactions  (1,306)
      
Weighted average common shares outstanding for adjusted diluted net income per share78,394  75,160 


 
CONDENSED BALANCE SHEET DATA
(UNAUDITED)
 
(In thousands)
 
   March 31,  
 2017
   December 31,
2016
        
Cash and cash equivalents                $124,113  $102,055 
Accounts receivable, net158,234  148,186 
Inventories, net239,809  217,263 
    
Bank line of credit855,000  665,000 
    
Stockholders' equity$852,491  $839,667 

 


CONDENSED STATEMENT OF CASH FLOWS
(UNAUDITED)
 
(In thousands)
 
 Three Months Ended
          
 March 31, 2017 March 31, 2016
Net cash provided by operating activities$28,882  $25,030 
Net cash used in investing activities(193,143) (6,730)
Net cash provided by financing activities185,039  9,952 
Effect of exchange rate changes on cash and cash equivalents1,280  702 
    
Net increase in cash and cash equivalents$22,058  $28,954 
    


RECONCILIATION OF NON-GAAP ADJUSTMENTS - GAAP OPERATING CASH FLOW TO
MEASURES OF FREE CASH FLOW AND FREE CASH FLOW CONVERSION
(UNAUDITED)
(In thousands)     
      
 Three Months Ended
March 31, 
  2017   2016 
GAAP net cash provided by continuing operating activities$  28,880  $  25,030 
      
      
Purchases of property and equipment from continuing operations (9,191)  (10,895)
Free cash flow 19,689   14,135 
      
Adjusted net income *$  30,889  $  28,263 
Adjusted free cash flow conversion   63.7%    50.0%
      
      
 Twelve Months Endied 
March 31, 
  2017   2016 
GAAP net cash provided by continuing operating activities**$  163,040  $  112,792 
      
Purchases of property and equipment from continuing operations (45,624)  (38,978)
Free cash flow 117,416   73,814 
      
Adjusted net income *$  137,990  $  112,921 
Adjusted free cash flow conversion   85.1%    65.4%
      
      
* Adjusted net income for quarters ended March 31, 2017 and 2016 are reconciled above.  Adjusted net income for remaining quarters in the trailing twelve months calculation have been previously reconciled and are publicly available in the Quarterly Earnings Call Presentations and the Historical Financial Results: Continuing Operations presentation on our website at investor.integralife.com under Events & Presentations.
** Operating cash flow excludes $42.8M of accreted interest payment associated with the 2016 Convertible Notes.
      
The Company calculates adjusted free cash flow conversion by dividing its free cash flow by adjusted net income.  The Company believes this measure is useful in evaluating the significance of the cash special charges in its adjusted earnings measures.
      


INTEGRA LIFESCIENCES HOLDINGS CORPORATION 
RECONCILIATION OF NON-GAAP ADJUSTMENTS - GUIDANCE 
             
         
 Recorded Year to Date  Projected Year Ended 
(In thousands, except per share amounts)March 31, 2017  December 31, 2017 
    Low  High 
GAAP net income$  6,394  $  39,250  $  43,750 
Non-GAAP adjustments:        
Global ERP implementation charges 2,427   7,400   7,400 
Structural optimization charges 1,586   19,000   19,000 
Acquisition-related charges 20,317   78,500   78,500 
Certain employee severance charges 125   125   125 
Discontinued product lines charges 1,025   1,025   1,025 
Intangible asset amortization expense 10,966   47,800   47,800 
Estimated income tax impact from adjustments and other items (11,951)    (44,000)  (44,000)
         
Total of non-GAAP adjustments 24,495   109,850   109,850 
Adjusted net income$  30,889  $  149,100  $  153,600 
         
GAAP diluted net income per share$0.08  $0.49  $0.55 
Non-GAAP adjustments detailed above (per share)$0.31  $1.39  $1.39 
Adjusted diluted net income per share$0.39  $1.88  $1.94 
         
Weighted average common shares outstanding for diluted net income per share 78,394   79,500   79,000 
         

 

GUIDANCE - SPECIAL CHARGES 
                       
ItemYTD
Amount
  FY
Guidance
  COGS SG&A  R&D  Amort. Interest
(Inc)Exp
  Tax 
Global ERP implementation charges$  2,427  $  7,400 $ —  $  7,400  $ —  $ — $ — $ — 
Structural optimization charges 1,586   19,000  10,500  8,500           
Acquisition-related charges 20,317   78,500  9,000  69,500          
Certain employee severance charges 125   125    125         
Discontinued product lines charges 1,025   1,025  1,025           
Intangible asset amortization expense 10,966   47,800  31,000      16,800     
Convertible debt non-cash interest                 
Estimated income tax impact from adjustments and other items (11,951)  (44,000)           (44,000)
                          
Total 24,495   109,850  51,525  85,525    16,800    (44,000)

 

Contact:

Investor Relations:
Angela Steinway
(609) 936-2268
angela.steinway@integralife.com

Michael Beaulieu
(609) 750-2827
michael.beaulieu@integralife.com

Media:
Laurene Isip
(609) 750-7984
laurene.isip@integralife.com